Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker LGND
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | John W. Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 500 | $162.5K | 10b5-1 | Nov 12, 2026 | — | Form 144 ↗ |
| Nov 12, 2026 | John W. Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 500 | $158.7K | 10b5-1 | Nov 11, 2026 | — | Form 144 ↗ |
| Nov 12, 2026 | Martine Zimmermann Director | LGND Ligand Pharmaceuticals Incorporated | 2,000 | $636.3K | — | Nov 12, 2026 | — | Form 144 ↗ |
| Nov 10, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | 3,000 | $960.1K | — | Nov 10, 2026 | Form 4 ↗ 2 days later · 3,000 shares | Form 144 ↗ |
| Nov 4, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | 282 | $90.2K | — | Nov 4, 2026 | Form 4 ↗ 2 days later · 282 shares | Form 144 ↗ |
| Nov 2, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | 700 | $221.6K | — | Nov 2, 2026 | Form 4 ↗ 1 day later · 2,111 shares | Form 144 ↗ |
| Oct 30, 2026 | Jason M Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | 1,209 | $385.2K | — | Oct 30, 2026 | Form 4 ↗ 4 days later · 2,111 shares | Form 144 ↗ |
| Oct 30, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | 202 | $64.7K | — | Oct 30, 2026 | Form 4 ↗ 4 days later · 2,111 shares | Form 144 ↗ |
| Sep 10, 2026 | Martine Zimmermann Director | LGND Ligand Pharmaceuticals Incorporated | 1,200 | $342.0K | — | Sep 10, 2026 | Form 4 ↗ 4 days later · 1,200 shares | Form 144 ↗ |
| Sep 3, 2026 | Andrew Reardon Officer | LGND Ligand Pharmaceuticals Incorporated | 15,000 | $4.3M | 10b5-1 | Sep 3, 2026 | Form 4 ↗ 5 days later · 5,000 shares | Form 144 ↗ |
| Aug 12, 2026 | Octavio Espinoza Officer | LGND Ligand Pharmaceuticals Incorporated | 31,641 | $9.1M | 10b5-1 | Aug 12, 2026 | Form 4 ↗ 2 days later · 31,641 shares | Form 144 ↗ |
| Aug 12, 2026 | Jason Haas Director | LGND Ligand Pharmaceuticals Incorporated | 7,138 | $2.1M | — | Aug 12, 2026 | Form 4 ↗ 2 days later · 7,138 shares | Form 144 ↗ |
| Jul 1, 2026 | Andrew Reardon Officer | LGND Ligand Pharmaceuticals Incorporated | 10,000 | $3.2M | 10b5-1 | Jul 1, 2026 | Form 4 ↗ 5 days later · 5,000 shares | Form 144 ↗ |
| Jun 16, 2026 | Stephen L. Sabba Director | LGND Ligand Pharmaceuticals Incorporated | 2,145 | $544.8K | — | Jun 16, 2026 | Form 4 ↗ 2 days later · 2,145 shares | Form 144 ↗ |
| Jun 12, 2026 | Jason Haas Director | LGND Ligand Pharmaceuticals Incorporated | 6,461 | $1.7M | — | Jun 12, 2026 | Form 4 ↗ 3 days later · 6,461 shares | Form 144 ↗ |
| Jun 11, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | 4,500 | $1.1M | — | Jun 11, 2026 | Form 4 ↗ 1 day later · 5,000 shares | Form 144 ↗ |
| Jun 10, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | 500 | $125.0K | — | Jun 10, 2026 | Form 4 ↗ 2 days later · 5,000 shares | Form 144 ↗ |
| Jun 10, 2026 | John L Lamattina Director | LGND Ligand Pharmaceuticals Incorporated | 4,519 | $1.1M | — | Jun 10, 2026 | Form 4 ↗ 2 days later · 4,591 shares | Form 144 ↗ |
| Jun 10, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | 5,000 | $1.2M | — | Jun 10, 2026 | Form 4 ↗ 2 days later · 5,000 shares | Form 144 ↗ |
| May 13, 2026 | John Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 1,575 | $352.0K | — | May 13, 2026 | Form 4 ↗ 1 day later · 2,034 shares | Form 144 ↗ |
| May 12, 2026 | John Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 459 | $102.8K | — | May 12, 2026 | Form 4 ↗ 2 days later · 2,034 shares | Form 144 ↗ |
| May 1, 2026 | John W. Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 467 | $107.3K | 10b5-1 | May 1, 2026 | Form 4 ↗ 13 days later · 2,501 shares | Form 144 ↗ |
| Apr 1, 2026 | John W. Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 467 | $95.0K | 10b5-1 | Apr 1, 2026 | Form 4 ↗ 1 day later · 467 shares | Form 144 ↗ |
| Mar 23, 2026 | Stephen L. Sabba Director | LGND Ligand Pharmaceuticals Incorporated | 1,000 | $207.9K | — | Mar 23, 2026 | Form 4 ↗ 2 days later · 1,000 shares | Form 144 ↗ |
| Mar 11, 2026 | Octavio Espinoza Officer | LGND Ligand Pharmaceuticals Incorporated | 3,057 | $649.0K | 10b5-1 | Mar 11, 2026 | Form 4 ↗ 2 days later · 3,057 shares | Form 144 ↗ |
| Mar 6, 2026 | John L Lamattina Director | LGND Ligand Pharmaceuticals Incorporated | 2,161 | $433.8K | — | Mar 6, 2026 | Form 4 ↗ 25 days later · 2,161 shares | Form 144 ↗ |
| Mar 4, 2026 | Andrew Reardon Officer | LGND Ligand Pharmaceuticals Incorporated | 20,000 | $4.1M | 10b5-1 | Mar 4, 2026 | Form 4 ↗ 2 days later · 5,000 shares | Form 144 ↗ |
| Mar 4, 2026 | Octavio Espinoza Officer | LGND Ligand Pharmaceuticals Incorporated | 13,423 | $2.7M | 10b5-1 | Mar 4, 2026 | Form 4 ↗ 2 days later · 13,423 shares | Form 144 ↗ |
| Mar 3, 2026 | Stephen L. Sabba Director | LGND Ligand Pharmaceuticals Incorporated | 2,034 | $409.9K | — | Mar 3, 2026 | Form 4 ↗ 2 days later · 2,034 shares | Form 144 ↗ |
| Feb 2, 2026 | John W. Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 467 | $89.7K | 10b5-1 | Feb 2, 2026 | Form 4 ↗ 2 days later · 467 shares | Form 144 ↗ |
| Jan 2, 2026 | John W. Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 467 | $88.1K | 10b5-1 | Jan 2, 2026 | Form 4 ↗ 4 days later · 467 shares | Form 144 ↗ |
| Dec 12, 2025 | Octavio Espinoza Officer | LGND Ligand Pharmaceuticals Incorporated | 1,804 | $339.7K | — | Dec 12, 2025 | Form 4 ↗ 4 days later · 1,804 shares | Form 144 ↗ |
| Dec 1, 2025 | John W. Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 467 | $93.3K | 10b5-1 | Dec 1, 2025 | Form 4 ↗ 2 days later · 467 shares | Form 144 ↗ |
| Nov 7, 2025 | Nancy Gray Director | LGND Ligand Pharmaceuticals Incorporated | 6,571 | $1.4M | — | Nov 7, 2025 | Form 4 ↗ 5 days later · 6,571 shares | Form 144 ↗ |
| Nov 7, 2025 | John L Lamattina Director | LGND Ligand Pharmaceuticals Incorporated | 4,179 | $858.6K | — | Nov 7, 2025 | Form 4 ↗ 5 days later · 4,179 shares | Form 144 ↗ |
| Nov 3, 2025 | John W. Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 467 | $89.2K | 10b5-1 | Nov 3, 2025 | Form 4 ↗ 2 days later · 467 shares | Form 144 ↗ |
| Oct 1, 2025 | John W. Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 467 | $82.5K | 10b5-1 | Oct 1, 2025 | Form 4 ↗ 2 days later · 467 shares | Form 144 ↗ |
| Sep 23, 2025 | Jason M Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | 10,000 | $1.7M | — | Sep 23, 2025 | Form 4 ↗ 1 day later · 10,000 shares | Form 144 ↗ |
| Sep 17, 2025 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | 10,000 | $1.7M | — | Sep 17, 2025 | Form 4 ↗ 7 days later · 10,000 shares | Form 144 ↗ |
| Sep 2, 2025 | John W. Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 467 | $75.5K | 10b5-1 | Sep 2, 2025 | Form 4 ↗ 2 days later · 467 shares | Form 144 ↗ |
| Aug 1, 2025 | John W. Kozarich Director | LGND Ligand Pharmaceuticals Incorporated | 467 | $61.2K | 10b5-1 | Aug 1, 2025 | Form 4 ↗ 4 days later · 467 shares | Form 144 ↗ |
| Jul 10, 2025 | John W. Kozarich Officer | LGND Ligand Pharmaceuticals Incorporated | 934 | $116.8K | 10b5-1 | Jul 10, 2025 | Form 4 ↗ 1 day later · 934 shares | Form 144 ↗ |
| Jun 23, 2025 | Andrew Thomas Reardon Officer | LGND Ligand Pharmaceuticals Incorporated | 500 | $57.0K | — | Jun 23, 2025 | Form 4 ↗ 1 day later · 500 shares | Form 144 ↗ |
| Jun 10, 2025 | Andrew Thomas Reardon Officer | LGND Ligand Pharmaceuticals Incorporated | 500 | $57.3K | — | Jun 10, 2025 | Form 4 ↗ 2 days later · 500 shares | Form 144 ↗ |
| May 15, 2025 | Andrew Thomas Reardon Officer | LGND Ligand Pharmaceuticals Incorporated | 1,000 | $104.0K | — | May 15, 2025 | Form 4 ↗ 18 days later · 1,000 shares | Form 144 ↗ |
| Mar 18, 2025 | Stephen L. Sabba Director | LGND Ligand Pharmaceuticals Incorporated | 2,406 | $255.0K | — | Mar 18, 2025 | — | Form 144 ↗ |
| Mar 4, 2025 | Espinoza Octavio Officer | LGND Ligand Pharmaceuticals Incorporated | 5,000 | $575.1K | — | Mar 4, 2025 | Form 4 ↗ 2 days later · 5,000 shares | Form 144 ↗ |
| Dec 23, 2024 | Espinoza Octavio Officer | LGND Ligand Pharmaceuticals Incorporated | 2,104 | $244.9K | — | Dec 23, 2024 | Form 4 ↗ 3 days later · 2,104 shares | Form 144 ↗ |
| Nov 27, 2024 | John L. Lamattina Director | LGND Ligand Pharmaceuticals Incorporated | 2,406 | $286.8K | — | Nov 26, 2024 | Form 4 ↗ 5 days later · 2,406 shares | Form 144 ↗ |
| Nov 12, 2024 | Matthew E. Korenberg Officer | LGND Ligand Pharmaceuticals Incorporated | 32,183 | $3.9M | — | Nov 11, 2024 | — | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 7:18 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances